Skip to main content
. 2013 Dec;20(12):1827–1835. doi: 10.1128/CVI.00519-13

Fig 6.

Fig 6

Comparison of current (B1G) and new (B2G) Bovigam (Prionics AG) kits using responses to individual antigens and PPDb minus PPDa with samples from control (n = 7) as well as M. bovis 95-1315- (n = 8), and M. bovis 10-7428-infected (n = 8) animals. (a) IFN-γ responses pooled over time, (b) responses to prechallenge (Commonwealth Serum Laboratories) and Lelystad (Prionics AG) PPDb minus PPDa, (c) responses to 4-week-postchallenge CSL and Lelystad PPDb minus PPDa, and (d) responses to 12-week-postchallenge CSL and Lelystad PPDb minus PPDa.